Signal Genetics has appointed Richard Bender its chief medical officer, effective Sept. 14. He will report directly to Signal President and CEO Samuel Riccitelli.
Bender has more than 30 years of experience in clinical oncology/hematology and medical diagnostics. Most recently, he consulted for various companies and was a long-term medical affairs consultant for Quest Diagnostics. Previous to that, he was vice president and CMO at Agendia, and before that, he was the medical director of hematology/oncology at Quest in San Juan Capistrano, California. He also held management positions at Johnson & Johnson Pharmaceutical and at Permanente Medical Group.